| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
and PML Expression in Acute Promyelocytic Leukemia Cells by Anti-PML Peptide Nucleic Acid1
Department of Experimental Oncology, Istituto Nazionale Tumori, 20133 Milan, Italy [L. M., E. M., C. G-P.], and Center for Biomolecular Recognition, IMBG, The Panum Institute, DK2200N Copenhagen, Denmark [P. E. N.]
The fusion protein promyelocytic leukemia (PML)/retinoic acid receptor (RAR)
is tightly linked to the pathogenesis of acute promyelocytic leukemia (APL); hence, it represents a tumor-associated, transformation-related molecule. In this study, three anti-PML adamantyl-conjugated peptide nucleic acid (PNA) oligomers previously described as in vitro inhibitors of PML/RAR
translation were combined and used to block PML/RAR
synthesis in NB4 cells. Cationic liposomes were used to achieve sufficient delivery of PNAs into the cells. Upon treatment of cells with the liposome/PNA mixture, enhanced cellular uptake of PNA (approximately 5-fold compared with control) was obtained. Concomitantly, a substantial reduction (>90%) of the expression of PML/RAR
was observed when all of the three PNAs were used together. This resulted in a dramatic effect on the number and viability of NB4 cells in culture after 48 h of treatment. This phenomenon was preceded by induction of apoptosis that could be observed 24 h after treatment. No sign of granulocytic differentiation was observed after treatment. These effects were also noted on other leukemic cell lines that express PML but not the fusion transcript. These results show that it is possible to deliver PNA into hematopoietic cells and obtain specific gene inhibition, and they suggest that a growth inhibitory effect on acute promyelocytic leukemia cells can be obtained through the block of PML/RAR
and PML expression.
This article has been cited by other articles:
![]() |
T. Shiraishi, R. Hamzavi, and P. E. Nielsen Subnanomolar antisense activity of phosphonate-peptide nucleic acid (PNA) conjugates delivered by cationic lipids to HeLa cells Nucleic Acids Res., August 1, 2008; 36(13): 4424 - 4432. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Tonelli, S. Purgato, C. Camerin, R. Fronza, F. Bologna, S. Alboresi, M. Franzoni, R. Corradini, S. Sforza, A. Faccini, et al. Anti-gene peptide nucleic acid specifically inhibits MYCN expression in human neuroblastoma cells leading to cell growth inhibition and apoptosis Mol. Cancer Ther., May 1, 2005; 4(5): 779 - 786. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Shiraishi and P. E. Nielsen Down-regulation of MDM2 and activation of p53 in human cancer cells by antisense 9-aminoacridine-PNA (peptide nucleic acid) conjugates Nucleic Acids Res., September 15, 2004; 32(16): 4893 - 4902. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Jiankuo, W. Xingbing, H. Baojun, W. Xiongwin, L. Zhuoya, X. Ping, X. Yong, L. Anting, H. Chunsong, G. Feili, et al. Peptide Nucleic Acid Antisense Prolongs Skin Allograft Survival by Means of Blockade of CXCR3 Expression Directing T Cells into Graft J. Immunol., February 1, 2003; 170(3): 1556 - 1565. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Dias and C. A. Stein Antisense Oligonucleotides: Basic Concepts and Mechanisms Mol. Cancer Ther., March 1, 2002; 1(5): 347 - 355. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |